Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.

Elmariah, Sarina; Chisolm, Sarah; Sciascia, Thomas; Kwatra, Shawn G

Elmariah, Sarina; Chisolm, Sarah; Sciascia, Thomas; Kwatra, Shawn G.

Afiliação

Elmariah S; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Chisolm S; Department of Dermatology, Emory University, Atlanta, Georgia.
Sciascia T; Veteran's Affairs VISN, Decatur, Georgia.
Kwatra SG; Trevi Therapeutics, New Haven, Connecticut.

JAAD Int ; 7: 156-163, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35497636

Palavras-chave

AE, adverse event; CI, confidence interval; HD, hemodialysis; KOR, κ-opioid receptor; MOR, µ-opioid receptor; NAL-ER, nalbuphine extended release; NRS, numerical rating scale; OR, opioid receptor; PN, prurigo nodularis; SD, standard deviation; UP, uremic pruritus; VAS, visual analog scale; WI-NRS, Worst ItchingNumerical Rating Scale; antipruritic; butorphanol; difelikefalin; end-stage renal disease; itch; nalbuphine; naltrexone; neural pathways; opioid; prurigo; pruritus; receptors; renal dialysis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article